These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 22438097

  • 41. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
    Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN.
    Cancer; 2013 Sep 15; 119(18):3334-42. PubMed ID: 23821538
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
    Olencki T, Peereboom D, Wood L, Budd GT, Novick A, Finke J, McLain D, Elson P, Bukowski RM.
    J Cancer Res Clin Oncol; 2001 May 15; 127(5):319-24. PubMed ID: 11355147
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W, Guo RP, Shi M.
    Chin J Cancer; 2017 Oct 23; 36(1):83. PubMed ID: 29061175
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
    Fountzilas G, Zisiadis A, Dafni U, Konstantaras C, Hatzitheoharis G, Papavramidis S, Bousoulegas A, Basdanis G, Giannoulis E, Dokmetzioglou J, Katsohis C, Nenopoulou E, Karvounis N, Briassoulis E, Aravantinos G, Kosmidis P, Skarlos D, Pavlidis N.
    Oncology; 2000 Apr 23; 58(3):227-36. PubMed ID: 10765125
    [Abstract] [Full Text] [Related]

  • 49. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME, McGarry W, Bready B, Dakhil SR, Belt RJ, Goodwin JW, Gray R, Hoff PM, Winn R, Pazdur R.
    J Clin Oncol; 1999 Oct 23; 17(10):3276-82. PubMed ID: 10506630
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    Allen MJ, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, Bate S, Moore J, Ahern R, Gore ME.
    Br J Cancer; 2000 Oct 23; 83(8):980-5. PubMed ID: 10993642
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
    Katamura Y, Aikata H, Kimura Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Ishikawa M, Hieda M, Kakizawa H, Chayama K.
    J Gastroenterol Hepatol; 2010 Jun 23; 25(6):1117-22. PubMed ID: 20074168
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J, Bao Q, Cao G, Zhu X, Yang R, Ji X, Xu L, Zheng K, Li W, Xing B, Wang X.
    Cardiovasc Intervent Radiol; 2020 Jul 23; 43(7):996-1005. PubMed ID: 31974744
    [Abstract] [Full Text] [Related]

  • 56. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
    Sunela KL, Koskinen S, Kellokumpu-Lehtinen PL.
    Cancer Chemother Pharmacol; 2010 May 23; 66(1):59-67. PubMed ID: 19771431
    [Abstract] [Full Text] [Related]

  • 57. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.
    Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M.
    World J Gastroenterol; 2005 Apr 28; 11(16):2526-9. PubMed ID: 15832431
    [Abstract] [Full Text] [Related]

  • 58. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M, Kawaoka T, Aikata H, Morio K, Kobayashi T, Hiramatsu A, Imamura M, Kawakami Y, Murakami E, Waki K, Honda Y, Mori N, Takaki S, Tsuji K, Kohno H, Kohno H, Moriya T, Nonaka M, Hyogo H, Aisaka Y, Chayama K.
    Anticancer Res; 2016 Jul 28; 36(7):3523-9. PubMed ID: 27354618
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB.
    JAMA; 2010 Nov 17; 304(19):2154-60. PubMed ID: 21081728
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.